Posted by Michael Wonder on 26 Oct 2018
Bayer receives approval for haemophilia A treatment Jivi
24 October 2018 - Extended half-life product that offers a reduction in dosing frequency and improved bleeding protection.
Bayer announced today that Health Canada has approved Jivi (Antihemophilic Factor [Recombinant, B-domain deleted, PEGylated]) for routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes in previously treated adults and adolescents 12 years of age or older. Health Canada also approved Jivi for control and prevention of episodic bleeding, and peri-operative management of bleeding (surgical prophylaxis.)
The recommended initial prophylactic regimen for Jivi is twice weekly, with the ability to dose every five days and further individually adjust to less or more frequent dosing based on bleeding episodes. This approval is based on results from the PROTECT VIII trial.
